Patrys has today released its Quarterly Activities Report and Appendix 4C Quarterly Cash Flow report for the quarter ended 31 March 2023.
Key achievements during the period include:
- Dosing for PAT-DX1 toxicology studies completed and on track for draft results in May
- Master Cell Bank and integration run for PAT-DX3 completed
- Preclinical study validating potential for PAT-DX3 in synthetic lethality strategies
- US PTO grants two new patents for deoxymab technology providing coverage until 2039
- Cash and short-term investment balance of $6.68M on 31 March 2023.